Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome.
Unknown statusNot applicableNCT04938713
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Ketamine and Esketamine intravenous perfusions can modulate chronic pain. The purpose of this study is to determine if Ketamine or Esketamine are favorable for outpatients suffering from fibromyalgia.
Study details
- Official title
- Comparison of Ketamine and Esketamine in Ambulatory Patients Treated for Fibromyalgia Syndrome in Pain Clinic. A Single-center, Prospective, Randomized, Double-blind, Crossover Study.
- Conditions
- Interventions
- Drug: Ketamine 50 MG/ML
- Drug: Esketamine 25 MG/ML
- Sponsor
- Centre Hospitalier Universitaire de Charleroi
- Collaborators
- Centre Hospitalier Universitaire de Liege
- Start date
- 2021-07-01
- Primary completion
- 2022-05-01
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Belgium
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male and female * Between 18 and 75 years old * Reads and writes French * Diagnosis of fibromyalgia syndrome according to Widespread Pain Index (WPI) and Symptom Severity Scale (SSS) score ≥ 13/31 * Both molecules (Ketamine and Esketamine) were administered at least once during an analgesic infusion session in Pain Clinic * Patient with regular medical follow-up by a pain specialist at least 3 times a year Exclusion Criteria: * Allergy or intolerance to Ketamine or Esketamine * Current infection, fever * Pregnant or breastfeeding woman * Serious cardiovascular disorders and severe hypertension * Increased pressure of cerebrospinal fluid and severe intracranial disease * Acute intermittent porphyria * Untreated epilepsy * Untreated glaucoma * Difficult or impossible intravenous access * Chronic Liver Disease Child-Pugh C
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04938713